Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078037 | 0.80 | ATM (0.39) | NPSR1MAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL12853918 | 0.76 | HTT (0.63) | NPSR1MAPTGFERHTTSMN1; SMN2 | |
| SCHEMBL5056593 | 0.75 | CYP3A4 (0.54) | CYP2C19CYP3A4MAPTHTTALDH1A1 | |
| SCHEMBL22281477 | 0.75 | CYP3A4 (0.54) | CYP2C19CYP3A4MAPTHTTALDH1A1 | |
| SCHEMBL3073777 | 0.74 | ALDH1A1 (0.51) | CYP2C19CYP3A4NPSR1MAPTGFER | |
| SCHEMBL20273673 | 0.73 | CYP3A4 (0.43) | CYP2C19CYP3A4NPSR1MAPTGFER | |
| SCHEMBL22047112 | 0.70 | MAPT (0.43) | CYP2C19CYP3A4NPSR1MAPTGFER | |
| SCHEMBL19305856 | 0.69 | LMNA (0.54) | MAPTSMN1; SMN2KDM4ELMNAPKM | |
| SCHEMBL6763359 | 0.67 | ALDH1A1 (0.54) | NPSR1MAPTGFERHTTALDH1A1 | |
| Nikethamide SCHEMBL246456 | 0.67 | HTT (0.65) | NPSR1MAPTGFERHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267711-A1 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF | CYTRX CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-7745465-B2 | Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof | CYTRX CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7148239-B2 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | CYTRX CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| US-20040019103-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | BIOREX RESEARCH & DEVELOPMENT CO. | 2004-01-29 | — | — | US | disclosed |
| US-6653326-B1 | For example, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-3-pyridinecarboximidoyl chloride maleate; inducing gene expression of an eukaryotic cell under physiological stress; antiallergens; autoimmune diseases; cardiovascular disorders | BIOREX RESEARCH & DEVELOPMENT CO. (HU) | 2003-11-25 | — | — | US | disclosed |
| EP-0801649-B1 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | BIOREX KUTATO FEJLESZTOE KFT (HU) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267711-A1 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF | HSPE1, HSF1, HSP90AB2P | CYP2C19 1717/4885CYP3A4 2351/4885NPSR1 3586/4885 |
| US-20040019103-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | HSPE1, HSF1, HSPA1A | CYP2C19 1527/4885CYP3A4 2236/4885NPSR1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.